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Poly-adenosine diphosphate-ribose polymerases (PARPs)
promote ADP-ribosylation, a highly conserved, funda-
mental posttranslational modification (PTM). PARP cata-
lytic domains transfer the ADP-ribose moiety fromNAD+
to amino acid residues of target proteins, leading tomono-
or poly-ADP-ribosylation (MARylation or PARylation).
This PTM regulates various key biological and pathologi-
cal processes. In this review, we focus on the roles of the
PARP family members in inflammation and host–patho-
gen interactions. Herewe give an overview the current un-
derstanding of the mechanisms by which PARPs promote
or suppress proinflammatory activation of macrophages,
and various roles PARPs play in virus infections. We
also demonstrate how innovative technologies, such as
proteomics and systems biology, help to advance this re-
search field and describe unanswered questions.
Polyadenosine diphosphate-ribose polymerases (PARPs)
promote ADP-ribosylation, one of the fundamental post-
translational modifications (PTMs) (Gupte et al. 2017).
This ubiquitous PTM regulates various key biological
and pathological processes, includingDNA repair, cell dif-
ferentiation, gene transcription, signal transduction path-
ways, energymetabolism, and epigenetics. PARPcatalytic
domains transfer the ADP-ribose moiety from NAD+ to
amino acid residues of target proteins, leading to mono-
or poly-ADP-ribosylation (MARylation or PARylation).
PARPmembers thus function as “writers” of ADP-ribose.
Among the 17 human PARPs, PARP1, PARP2, PARP5A,
andPARP5BpromotePARylation,whilemostothermem-
bers (e.g., PARP3, PARP4, PARP6, PARP14, and PARP15)
catalyze MARylation (Hottiger 2015; Ryu et al. 2015;
Gupte et al. 2017). A newnomenclature has thus been pro-
posed to call them the diphtheria toxin-like ADP-ribosyl-
transferases (ARTDs); e.g., ARTD1 for PARP1 (Hottiger
et al. 2010).DifferencesbetweeneachPARP lead todiverse
functions for PARPs in biological processes such as the in-
nate immune response (Fig. 1).
PARP family members contain a few structural do-
mains, in addition to the catalytic domain. One of such
domains is the macrodomain that is contained in
PARP9, PARP14, and PARP15, for which they are called
“macro” PARPs. Macrodomains bind to, and in some cas-
es hydrolyze, ADP-ribose in the free or protein-bound
form (“readers” of ADP-ribosylation) and influence
many biological processes (Rack et al. 2016). Evidence
has linked the MacroPARPs PARP9 and PARP14 in mul-
tiple types of cancers, particularly lymphomas (Aguiar
et al. 2000; Cho et al. 2009). PARP14 may also play an im-
portant role in cell morphology (Vyas et al. 2013). We
found the interplay of PARP9 and PARP14 in the regula-
tion of macrophage activation (Iwata et al. 2016), as de-
scribed in this review.
Different cellular distributions of PARPs may also
indicate their distinctive targets and functions (Vyas et al.
2013). While PARP1 is only found in the nucleus, PARP6,
PARP8, PARP12, PARP13, PARP15, and PARP16 aremost-
ly located in the cytoplasm. PARP2, PARP3, PARP4,
PARP5A, PARP5B, PARP7, PARP9, PARP10, PARP11,
and PARP14 are seen in both the nucleus and cytoplasm.
ADP-ribolylation is reversed by “erasers” such as poly-
ADP-ribose glycohydrolase (PARG), ADP-ribosylhydro-
lase 3 (ARH3), and macrodomains such as Mdo2 (Miwa
and Sugimura 1971; Oka et al. 2006; Jankevicius et al.[Keywords: ADP-ribosylation; PARP; atherosclerosis; host–pathogen
interactions; immunity; inflammation; macrophage; vascular disease]
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2013; Rosenthal et al. 2013). PARG is a potent enzyme
that degrades poly-ADP-ribose, with several isoforms
that are derived from the single PARG gene through alter-
native splicing (i.e., 110-, 102-, 99-, and 60-kDa proteins).
The 110-kDa isoform,mostly seen in the nucleus, appears
to play a dominant role in the PAR degradation. PARG
cannot erase ADP-ribose when bound to proteins and
leaves MARylated amino acid residues. PARG is a useful
tool that enables researchers the ability to enrich for
MARylated peptides for mass spectrometry analysis of
ADP-ribosylation (Higashi et al. 2019).
PARPS in immune cells: a focus on inflammation
Immune cells serve an important role in the immune sys-
tem and differentiate into various subsets that perform a
spectrum of unique functions. The balance of the number
of different immune cell types and their activation levels
is crucial for health and disease. Overwhelming evidence
has associated chronic inflammation with various patho-
logical conditions and their potential causes, including
atherosclerosis, cardiovascular events, cancer, autoim-
mune diseases, metabolic disorders, neurological diseas-
es, and aging (Johnston et al. 1987; Gisterå and Hansson
2017; Tabas and Lichtman 2017; de Vries and Quax
2018; Gomez et al. 2018; Aday and Ridker 2019; Bercovici
et al. 2019; Di Benedetto et al. 2019; Guner and Kim 2019;
Horwitz et al. 2019; O’Rourke et al. 2019; Othman et al.
2019; Trott and Fadel 2019). Many investigations have fo-
cused on the major role of macrophages in such contexts
and mechanisms for their proinflammatory activation
(Murray and Wynn 2011; Wynn and Vannella 2016; Gis-
terå and Hansson 2017; Tabas and Lichtman 2017; Dec-
ano and Aikawa 2018; Funes et al. 2018; Swirski and
Nahrendorf 2018; O’Rourke et al. 2019). Various sig-
nal-transduction pathways participate in macrophage
activation, which are often regulated by PTMs such as
phosphorylation and acetylation (Tietzel and Mosser
2002; Park et al. 2011; Zhou et al. 2014; Nakano et al.
2016; Vergadi et al. 2017; Dean et al. 2019). This section
focuses on the impact of PARPs and ADP-ribosylation in
macrophage activation and also summarizes their roles
in the biology of other immune cells.
PARP1 induces macrophage activation
and inflammation
Evidence suggests that ADP-ribosylation participates in
inflammation (Bai and Virág 2012; Rosado et al. 2013;
Kunze and Hottiger 2019). PARP1 has been implicated
in the mechanisms for responses (e.g., proinflammatory
cytokine expression) of macrophages or macrophage-like
cell lines to pathogen-associated molecular patterns
(PAMPs), including lipopolysaccharide (LPS) (Hassa et al.
2005; Liu et al. 2012a; Yang et al. 2014; Minotti et al.
2015; Bohio et al. 2019). Some responses involve the inter-
play between PARP1 and nuclear factor κB (NF-κB), a key
BA
Figure 1. PARPs regulate the innate immune response atmany different points. (A) Mechanisms used byMARylating and nonenzymatic
PARPs to modulate IFN and proinflammatory cytokine induction. (i) PARP13 can bind to RIG-I, which promotes its oligomerization and
the initiation of the cascade. (ii) PARP13 can also bind to IFN mRNA and target it for degradation. (iii) PARP12 was shown to bind TRIF
and enhance NFκB-dependent gene expression. (iv) PARP7 can ADP-ribosylate TBK-1, which inhibits it from phosphorylating IRF3.
(v) PARP10 can interactwith andADP-ribosylateNEMO,which prevents the activation of IKKs. (vi) PARP14 promotesH3K27 acetylation
and recruitment of Pol II to IFN promoters. (vii) Upon phosphorylation, PARP1 can poly-ADP-ribosylate NFκB and promote its activity.
(B) Mechanisms used byMARylating and nonenzymatic PARPs tomodulate IFN-I signaling. (i) PARP11 binds to and ADP-ribosylates the
E3 ubiquitin ligase β-TrCP. This allows β-TrCP to interact with and ubiquitinate IFNAR, which targets it for proteasome-dependent deg-
radation. (ii) PARP9 andDTX3L interact with and ubiquitinate histone protein H2BJ, which leads to chromatin remodeling that enhances
expression of a subset of ISGs. (P) Phosphate group; (ADPr) ADP-ribose; (Ac) acetyl modification; (yellow ciricle) ubiquitin.
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transcription factor in immunity and various other biolog-
ical processes (Hassa and Hottiger 1999; Hassa et al. 2005;
Liu et al. 2012a; Minotti et al. 2015; Bohio et al. 2019;
Kunze and Hottiger 2019). Using PARP1-deficient mice
Oliver et al. (1999) provided evidence that PARP1 pro-
motes NF-κB activation in macrophages in vivo. This
study demonstrated that Parp1 deletion causes resis-
tance to LPS-induced endotoxic shock by NF-κB-depen-
dent iNOS induction and NO production. Recent
evidence suggests that phosphorylation of PARP1 results
in PARylation of the NF-κB subunit p65/RelA, which in-
duces the transcription of NF-κB-regulated genes (Fig.
1A; Bohio et al. 2019). PARP1 also induces the release of
the high-mobility group box 1 (HMGB1), a proinflamma-
tory factor, from the nucleus to the cytoplasm in macro-
phages, which requires its PARylation and subsequent
acetylation (Ditsworth et al. 2007; Yang et al. 2014).
PARP1 also exerts proinflammatory effects on other mac-
rophage-related cell types such as Kupffer cells in the fatty
liver andmicroglia in the injured brain (Ullrich et al. 2001;
Mukhopadhyay et al. 2017). In some cases, PARP-1-in-
duced activation of proinflammatory mediators, such as
NF-κB, do not depend on its enzymatic activity, suggest-
ing mechanisms used by PARP1 to impact inflammation
depend on the context or its targets (Hassa et al. 2005;
Minotti et al. 2015).
The role of nicotinamide adenine dinucleotide (NAD±)
in PARP1-mediated macrophage activation
PARPs catalyze the transfer of ADP-ribose from NAD± to
target proteins. Hence, NAD± is consumed by PARPs, and
the activity of PARPs depends on the availability of NAD±
(Gupte et al. 2017). A recent report indicates that cell-
autonomous production of NAD± via the kynurenine
pathway (KP) is required to induce normal inflammatory
macrophage activation and that the de novo NAD± syn-
thesis can be impaired in aged macrophages (Minhas
et al. 2019). Another study proposed a mechanism linking
the NAD± salvage pathway to LPS-induced PARP1 con-
sumption of NAD± (Cameron et al. 2019). In LPS-stimu-
lated macrophages, an increase in reactive oxygen
species induces DNA damage, which in turn activates
PARP1, leading to a reduction of available NAD±. Nico-
tinamide phosphoribosyltransferase (NAMPT) is there-
fore increased to maintain NAD± levels, which is crucial
for normal inflammatory macrophage activation.
PARP1 participates in the biology of other immune cells
PARP1 modulates the differentiation of T cells into effec-
tor T cells such as T helper 1 (Th1), T helper 2 (Th2), and
regulatory T cells (Tregs) (Saenz et al. 2008; Nasta et al.
2010). PARP1 deficiency in murine T cells leads to the
increased expression of the Th1 cytokine interferon-γ
(IFN-γ) and the decreased production of the Th2 cytokine
interleukin 4 (IL-4) (Saenz et al. 2008). IL-4 suppresses
IFNγ secretion and Th1 differentiation, and PARP1 pro-
motes IL-4 expression via chromatin modifications at
the IL-4 locus (Saenz et al. 2008). Although PARP1 is
not involved in the differentiation of naïve T cells into T
helper 17 (Th17) cells, it does impact Tregs, as these cells
are augmented in multiple organs in PARP1-deficient
mice (Nasta et al. 2010). Using PARP1-deficient mice,
Nasta et al. (2010) demonstrated that PARP1 supresses
the expression of Foxp3 and thus generation of Tregs via
modulation of the chromatin structure and/or regulation
of the transcription factors. Additional studies used
PARP1-deficiet mice further demonstrated mechanisms
for PARP1-regulated suppression of Tregs via transform-
ing growth factor β (TGF β) receptors (Zhang et al. 2013).
Recent reports demonstrate the interactive role of
PARP1 and PARP2 in maintaining the number and func-
tion of T cells and promoting the development and func-
tion of B cells (Navarro et al. 2017; Galindo-Campos
et al. 2019). Defective thymocyte maturation is observed
in PARP1/PARP2-deficient mice, and accordingly T-cell
numbers in peripheral blood are reduced (Galindo-Cam-
pos et al. 2019). In PARP1/PARP2-deficient mice, the de-
velopment of bone marrow B cells is impaired, leading to
the reduction of transitional and follicular B cells (Nav-
arro et al. 2017). PARP1 also plays a role in thematuration
and function of dendritic cells by regulating the produc-
tion of IL-10 and IL-12 (Aldinucci et al. 2007).
PARP1 promotes experimental cardiovascular disorders
A series of in vivo studies from the Boulares and Matter
groups (Oumouna-Benachour et al. 2007; von Lukowicz
et al. 2008; Hans et al. 2009, 2011) used PARP1-deficient
mice to demonstrate that PARP1 promotes the develop-
ment of various cardiovascular disorders. Two studies
reported that PARP1 deficiency in apolipoprotein E-defi-
cient (ApoE−/−) mice reduces the size, macrophage and
T-cell content, death of macrophage foam cells, necrotic
core, NF-kB activation, and adhesionmolecule expression
in experimental atherosclerotic lesions, typical features of
human plaques prone to acute thrombotic events
(Oumouna-Benachour et al. 2007; von Lukowicz et al.
2008). Parp1 deletion attenuates dyslipidemia-induced
vascular dysfunction in ApoE−/− mice seemingly via
maintenance of eNOS activity (Hans et al. 2011). PARP1
deficiency furthermore improves delated cardiomyopha-
thy and concomitantly increases tissue inhibitor ofmetal-
loproteinase 2 (TIMP2) inApoE−/−mice (Hans et al. 2009).
PARP9 and PARP14 regulate macrophage activation
While many reports suggested multiple proinflammatory
roles for PARP1, contributions of other PARP family
members in macrophage activation remain incompletely
understood. We demonstrated that PARP9 and PARP14
coregulate proinflammatory activation of human macro-
phages (Iwata et al. 2016). In this study we took a sys-
tems-biology approach involving unbiased proteomics,
bioinformatics, and network analysis to identify potential
molecular switches of the balance of proinflammatory
versus non/anti-inflammatory macrophage phenotypes
as potential therapeutic targets. We performed proteo-
mics of human and mouse macrophage-like cell lines
The role of PARPs on the immune response
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treated with IFNγ or IL-4, which represent so-called proin-
flammatory M1 versus non/anti-inflammatory M2 cells.
We processed our proteomics data of >5000 proteins
with a conventional filtering method as well as our origi-
nal clustering method (Ricchiuto et al. 2015) to identify
molecules that increased with IFNγ and decreased with
IL-4 (Iwata et al. 2016). Interestingly, the only protein
that emerged from this stringent criteria was PARP14.
We also recognized that PARP9 showed similar responses.
The same study demonstrated in vitro that PARP14
suppresses proinflammatory IFNγ–STAT1 signaling and
activates the anti-inflammatory IL-4-STAT6 pathway in
primary humanmacrophages (Fig. 2; Iwata et al. 2016). Si-
lencing of PARP14 by siRNA accelerated the induction of
proinflammatory cytokines and chemokines (e.g., TNFα,
IL-1β, and CCL2/MCP-1) in IFNγ-treated macrophages
and suppressed anti-inflammatory molecules (e.g.,
MRC1and Arg1) in IL-4-treated cells. PARP9 silencing
generally exerted opposing effects. PARP9 also appeared
to interfere with PARP14’s suppressive action on the
IFNγ–STAT1 axis, thus promoting proinflammatory mac-
rophage activation (Fig. 2). Cell-free enzyme reactions
with mass spectrometry as a read-out further indicated
that ADP-ribosylation of STAT1 by PARP14 may reduce
phosphorylation of this proinflammatory mediator. How-
ever, the mechanisms used by PARP14 to interact with
STAT1 and influences its ADP-ribosylation and phos-
phorylation requires further investigations.
Due to thewell-recognized knowledge that targets iden-
tified in basic science often fail in the clinical stage, we
performed network analysis that closely linked the net-
work of PARP9, PARP14, and their first neighbor interac-
tors with the human coronary artery disease gene module
(Fig. 3). As predicted, in vivo studies in Parp14−/− mice
demonstrated that PARP14 participates in the pathogene-
sis of arterial diseases. Consistent with in vitro studies,
PARP14 deficiency indeed mitigated lesion development
and inflammatory burden in models of coronary artery
disease in mice (Iwata et al. 2016).
The anti-inflammatory role of PARP14 reported by us
are consistent with other reports. Iqbal et al. (2014) dem-
onstrated in macrophages that PARP14 reduces mRNA
stability and thus expression levels of tissue factor, a sur-
face glycoprotein that plays a major thrombogenic role in
macrophage-rich atherosclerotic lesions. PARP14’s asso-
ciation with anti-flammatory STAT6 was first described
using a yeast two-hybrid screen (Goenka and Boothby
2006). Although subsequent studies were not done in
the context of macrophage activation, they indicated
that PARP14’s enhancement of IL-4 STAT6’s transcrip-
tional activity may be more relevant to its promoter bind-
ing functions rather than its potential to ADP-ribosylate
STAT6 itself (Fig. 2; Goenka et al. 2007; Mehrotra et al.
2011). For instance, PARP14 can act as a transcriptional
repressor of STAT6 target genes, but activation by IL-4
leads to its autoribosylation and dissociation of PARP14
from a DNA-protein complex, thereby promoting STAT6
binding instead (Fig. 2; Goenka et al. 2007; Mehrotra et al.
2011). Thus, despite the accumulating evidence that
PARP14 promotes an anti-inflammatory state, there
does not yet exist enough information to disentangle
PARP14’s enzymatic functions from that of its protein-in-
teraction functions, and how each of these functions may
maintain an anti-inflammatory response, irrespective of
the cytokine or stimulus.
Evidence established that macrophages are a heteroge-
neous group of cells, as represented by the well-known
theory of M1 versus M2 polarization. Recent understand-
ing, however, suggests that macrophage heterogeneity is
more complex and multidimensional than the M1/M2
dichotomy (Murray et al. 2014; Nahrendorf and Swirski
2016; Decano and Aikawa 2018). In our study, single-cell
analysis demonstrated that IFNγ-elicited macrophages re-
main largely heterogeneous, consisting of a few clusters
rather than uniformly “polarized” toward an activated
phenotype (Iwata et al. 2016). Gene similarity maps dem-
onstrated close interactions between PARP9, PARP14,
STAT1, and STAT6, supporting our in vitro data described
above.
PARP14 regulates lymphocyte biology
Several pieces of evidence demonstrate that PARP14 pro-
motes the differentiation of naïve T cells into Th2 cells by
Figure 2. A partial model of PARP14 and
PARP9 function in macrophage activation.
In vivo and in vitro studies pertaining to
IFNg signaling in primarilymacrophages sug-
gest that PARP14mitigates proinflammatory
phosphorylated STAT1 via ADP-ribosyla-
tion, and that PARP9 may act to inhibit
PARP14’s enzymatic activity (Iwata et al.
2016). In vitro studies pertaining to IL-4 sig-
naling in the context of B-cell biology suggest
that in nonstimulating conditions PARP14 is
a suppressor of STAT6 target genes. In re-
sponse to IL-4, PARP14 is thought to become
enzymatically active and dissociate from the
promoter(s), thereby allowing phosphorylated STAT6 to bind and activate target genes (Mehrotra et al. 2011). A green question mark in-
dicates that the fate of ADP-ribosylated substrates is not known. The IFNγ and IL-4 mechanisms appear distinct, but they may be partial
and complementary pictures of a complex biology.
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regulating STAT6-dependent Gata3 expression and that
PARP14-deficient mice show reduced symptoms of aller-
gic airway disease (Mehrotra et al. 2013; Riley et al. 2013).
PARP14 enhances STAT3-dependent Th17 differentia-
tion (Mehrotra et al. 2015). PARP14 is also implicated in
immunoglobulin class switching in B cells by enhancing
the IL-4 and STAT6 signal, which produces the IgE iso-
type, a major factor in allergic hypersensitivity (Mehrotra
et al. 2011).
Other PARPs in macrophage biology
As discussed, while several studies have reported how
PARP1, PARP2, PARP9, and PARP14 promote or suppress
macrophage activation via signaling pathways (e.g. NF-κB,
IFNγ–STAT1, and IL-4–STAT6), the evidence remains
scant on the roles that other PARPs play in macrophage
biology. LPS increases the mRNA expression of PARP3,
PARP4, PARP7, PARP8, PARP10, PARP11, PARP12,
and PARP13 in murine bone marrow-derived macrophag-
es, but there are no known functions for these PARPs in
macrophage biology (Caprara et al. 2018). Other reports
have linked PARP10 and PARP12 with NF-κB signaling
(Verheugd et al. 2013; Welsby et al. 2014). Although these
lines of evidence may suggest roles of PARPs other than
PARP1, PARP2, PARP9, and PARP14 in macrophage biol-
ogy, more investigations are needed to better understand
how these PARPs participate in macrophage activation
and inflammatory diseases.
PARPs in cancer immunology
PARPs have been targets for drug development, particu-
larly in the cancer field. The most active targets include
PARP1, and more recently PARP14 (Berger et al. 2018;
Qin et al. 2019). Studies that used the small molecule in-
hibitors demonstrated that PARP suppression reduces
proinflammatory responses or enhances anti-inflammato-
ry functions of macrophages (Haskó et al. 2002; Wang
et al. 2013; Shrestha et al. 2016; Dharwal et al. 2019).
Recent work showed that PARP inhibition in combina-
tion with PD-1/PD-L1 blockade could be effective for
BRCA1-deficient tumors by activating antigen presenting
cells such as dendritic cells via the cGAS-STING pathway
(Jiao et al. 2017; Ding et al. 2018; Dunphy et al. 2018). Ma-
jor effects reported in these studies may reflect PARP1
suppression. These inhibitors, however, are not strictly
specific for PARP1 and their effects on other PARP mem-
bers and targets other than PARPs thus need to be ad-
dressed (Wahlberg et al. 2012).
Activated macrophages link ADP-ribosylation with
protein homeostasis
A global view of PARP activity on immunity undoubted-
ly requires proteomics. However, even with the most
advanced mass spectrometry technologies available, dis-
entangling the unique and overlapping functions of






























Figure 3. Computational prediction of an
association between the PARP9–PARP14
network and human inflammatory diseases.
The network of PARP14 (blue)–PARP9 (pur-
ple) consists of proteins that directly interact
with these PARPs (blue and orange nodes, re-
spectively).P-values indicate the significance
of closeness between the PARP14–PARP9
first neighbors in the interactome (the
PARP9–PARP14 module) and gene modules
ofhumandiseases suchascoronaryarterydis-
ease compared with random expectation. Re-
produced from Iwata et al. (2016).
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studies have begun to interrogate the complex biology of
the PARP family members in the context of immunity.
Nearly 30 years ago, radioactive labeling strategies dem-
onstrated an increase inADP-ribosylation signal in human
monocyte-derived macrophages in response to IFNγ (Ber-
ton et al. 1991). In addition, there was no increase in
PARP1mRNA, implicating additionalmechanisms rather
than an increase in total PARP1 levels for the increase in
ADP-ribosylation. Using quantitative proteomics, we
made a similar observation in IFNγ-treated THP-1 and
RAW264.7 macrophage-like cell lines (Iwata et al. 2016).
Moreover, PARP14 and PARP9 exhibited the increased ex-
pression following IFNγ exposure and had the opposite re-
sponse to IL-4, decreasing in abundance over the
stimulation period. These contrasting proinflammatory
and anti-inflammatory responses by PARP9 and PARP14
weredistinct from the other PARPsmeasured in the study.
More specifically, their responses to IFNγwere character-
istic of known cytokine inducible genes, STAT1, NMI (N-
myc interactor), OAS2, IFIH1, and IFIT3, among several
others. This study thus provided a plausible scenario
where the increase in global ADP-ribosylation in macro-
phages could be mediated in part by PARP14 (Iwata et al.
2016).
In a separate study, using quantitative proteomics in
combination with shRNA-mediated knockdown experi-
ments, PARP14 interactors were pursued in the context
of LPS signaling in RAW264.7 cells (Caprara et al. 2018).
A PARP14 coimmunoprecipitation of these RAW264.7
cells after LPS treatment found that SQSTM1 (Seques-
tome-1, a receptor linking autophagy and ubiquitylation),
PARP9, DTX3L, andNMIwere immunoprecipitated with
a PARP14 antibody specifically in PARP14 wild-type but
not PARP14 knockdown cells, indicating that these pro-
teins form a PARP14–protein interaction network in re-
sponse to LPS.
Protein–protein interactions alone do not clarify the
role of PARP enzyme activities in immunity. To date,
only one study has investigated ADP-ribosylated sub-
strates in immune cells on a global level (Higashi et al.
2019). Since ADP-ribosylome studies are technically
challenging to perform; they rely on specialized proteo-
mic workflows to enrich and sequence ADP-riboyslated
peptides (Martello et al. 2016; Larsen et al. 2017). We
used two independent approaches to enrich the ADP-
ribosylome of IFN-γ-treated THP-1 cells. One approach
used an anti-PARylation antibody enrichment that pro-
vided candidate ADP-ribosylated proteins, and the other
enriched for MARylated peptides via their affinity for a
macrodomain to identify ADP-ribosylated proteins (Higa-
shi et al. 2019). The majority of proteins identified from
both approaches combined, comprised ribosome/RNA-
binding proteins. These findings were not surprising
since this protein class is highly abundant, and thereby
more conducive to identifying ADP-ribosylated peptides.
Other ADP-ribosylated proteins were associated with
pathways involved in neutrophil degranulation and acti-
vation, IL-12 signaling, and glycolysis. Moreover, ADP-
ribosylation of a subset of the ribosome/RNA-binding
proteins increased in response to IFNγ, as did ADP-ribo-
sylated forms of PARP14 and PARP9, and interestingly
SQSTM1, the ubiquitin pathway associated protein iden-
tified as a candidate PARP14 binding partner (Caprara
et al. 2018). These studies point toward ADP-ribosylation
linking macrophage activation with protein homeostasis,
as indicated by the changes in ADP-ribosylation in nu-
merous translational machinery; and by the emergence
of proteins involved in ubiquitination (Higashi et al.
2019).
PARPS, ADP-ribosylation, and host–pathogen
interactions
ADP-ribosylation is well-known to play an important role
in many host–pathogen interactions. For instance, many
important bacterial toxins are ADP-ribosyltransferases
(ARTs). Bacterial pathogens such as B. pertussis, V. chol-
era, P. aeruginosa,C. botulinum, S. aureus, and E. coli en-
code for ARTs that target proteins such as elongation
factor 2, actin, and Rho GTPases that lead to cell death
(Holbourn et al. 2006). As discussed above, mammals
also encode for a diverse set of ARTs, most of which are
termed PARPs, that impact infections. Here we discuss
mammalian encoded PARPs that are involved in host–
pathogen interactions, focusing on virus infections.
Mammalian PARPs display several properties indicative
of involvement in host–pathogen interactions
PARPs interact with pathogens in many ways, and here
we describe specific cases where they either promote or
restrict virus replication and the innate immune response.
This discussion is summarized in Table 1 and Figure 1.
However, we start by discussing characteristics that indi-
cate an important role for PARPs in the host response to
infection.
First, many mammalian PARPs are stimulated by the
production of IFN (IFN-stimulated genes [ISGs]), and
thus are part of the mammalian antiviral defense system
(Atasheva et al. 2012; Zhang et al. 2015; Eckei et al.
2017; Li et al. 2018; Grunewald et al. 2019a). Also, several
mono-ADP-ribosylating PARPs are rapidly evolving, indi-
catingongoing conflictwithpathogens.ThePARPdomain
of PARP13, a disordered region of PARP4, and the macro-
domain(s) of the three macro-PARPs, PARP9, PARP14,
and PARP15, are all under positive selection (Kerns et al.
2008; Daugherty et al. 2014). Furthermore, Parp14 and
Parp15 have undergone multiple rounds of gene loss and
duplication, which creates novel gene products needed
for continual adaptation to new pathogens.
Several PARP proteins are also present in stress gran-
ules, which are important membrane-less organelles
that function to restrict the translation of RNAwhen cells
are under stress, such as during a virus infection. They are
often characterized by the presence of TIA1, TIAR, and
G3BP1, but are known to contain several hundred pro-
teins (McCormick and Khaperskyy 2017). Interestingly,
several proteins in stress granules are ADP-ribosylated,
and PARPs, including 5a, 12, 13, 14, and 15, are known
Fehr et al.
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constituents of stress granules (Leung et al. 2011). It has
been proposed that polyADP-ribose facilitates the concen-
tration of RNA-binding proteins in stress granules and
other nonmembranous structures and thereby promote
their oligomerization (Leung 2014).
Some virus families encode for a macrodomain protein
that reverses cellular ADP-ribosylation
Several decades ago, a conserved domain was identified in
all coronaviruses (CoVs), togaviruses, and hepatitis E virus
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Caprara et al. 2018; Grunewald
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to decreased IFN production
Guo et al. 2019
aPARP9 is only known to be active when bound to DTX3L.
(Green) DNA-dependent PARPs; (blue) ZnF PARPs; (yellow) macro-PARPs; (orange) other-PARPs.
(HIV-1) Human immunodeficiency virus; (MLV) murine leukemia virus, (MPSV) myeloproliferative sarcoma virus; (EBV) Epstein-Barr
virus; (KSHV) Kaposi’s sarcoma herpesvirus; (PRRSV) porcine reproductive and respiratory syndrome virus; (HSV-1) herpes simplex
virus-1; (IAV) influenza A virus; (SINV) sindbis virus; (VEEV) Venezuelan equine encephalitis virus; (RV) rubella virus; (γ-2 HV) γ-2
herpesvirus; (γHV-68) murine γ-herpesvirus-68; (EMCV) encephalomyocarditis virus; (VSV) vesicular stomatitis virus; (CHIKV) chi-
kungunya virus; (ZIKV) Zika virus; (MHV) murine hepatitis virus; (ALV-J) avian leukosis virus subgroup J; (SFV) Semliki forest virus;
(RRV) Ross River virus; (EBOV) Ebola virus; (MARV) Marburg virus; (EV-A71) enterovirus strain A71; (HBV) hepatitis B virus.
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that was termed the “X” domain (Gorbalenya et al. 1991;
Koonin et al. 1992). These domains are structurally ho-
mologous to the nonhistone part of themacroH2A protein
and are now known as macrodomains (Allen et al. 2003).
Macrodomains from all three viral families bind mono-
and poly-ADP-ribose, and can efficiently remove
mono-ADP-ribose from proteins by hydrolysis, strongly
indicating a role for ADP-ribosylation in either promoting
or inhibiting the replication of these viruses (Egloff et al.
2006; Li et al. 2016). Several studies on the CoV and alpha-
virus macrodomains have established that this protein
domain is critical for either replication or pathogenesis
(Eriksson et al. 2008; Park and Griffin 2009; Fehr et al.
2015, 2016; McPherson et al. 2017). Recent studies using
chikungunya virus (CHIKV) macrodomain mutants
showed that macrodomain ADP-ribose binding facilitated
initiation of virus replication, while hydrolase activity
was essential for the amplification of replication complex-
es (Abraham et al. 2018). Infection with ADP-ribosylhy-
drolase (ARH)-deficient CoVs, including severe acute
respiratory syndrome (SARS)-CoV and murine hepatitis
virus (MHV), led to higher levels of IFN and other cyto-
kines, indicating that it may block the innate immune re-
sponse (Fehr et al. 2016; Grunewald et al. 2019a). The
ARH-deficient MHV replicates poorly in primary macro-
phages, and importantly, this defect could be partially res-
cued by PARP inhibitors, directly indicating PARPs in the
antiviral response to CoVs (Grunewald et al. 2019a). How-
ever, it remains unknown what proteins may be targeted
by the viral macrodomains (for reviews, see Fehr et al.
2018; Leung et al. 2018).
The roles of PARP1 and the Tankyrase PARPs in virus
replication.
Some of the first reports of PARPs and ADP-ribosylation
impacting virus infection focused on the role of PARP1
on retrovirus and HIV-1 integration and replication.
Gäken et al. (1996) first demonstrated that PARP inhibi-
tors led to reduced retroviral integration into host chroma-
tin. They further used antisense oligonucleotides and
overexpression of dominant-negative PARP1 to confirm
that PARP activity is required for integration of retroviral
vectors. Other groups further demonstrated the impor-
tance of PARP activity in retrovirus andHIV-1 integration
into host chromosomes using siRNA transfected and
PARP1-deficient cells (Ha et al. 2001; Kameoka et al.
2005). Mechanistically, it was suggested that PARP1
may help resolve a 4- to 6-bp gap in the genome produced
during integration (Ha et al. 2001). PARP1 activity may
also impact HIV-1 transcription and replication (Kameoka
et al. 1999, 2004). However, these results have been con-
founded by other reports that demonstrated either no evi-
dence that PARP1 was required for efficient HIV-1
integration or replication (Baekelandt et al. 2000; Ariumi
et al. 2005), or evidence that PARP1 can repress HIV-1
or retrovirus infection (Parent et al. 2005; Bueno et al.
2013). Bueno et al. (2013) found that PARP1 inhibited ret-
roviral infection in a chicken B lymphoblastoid cell line,
while Parent et al. (2005) showed that PARP1 could bind
to the transactivation response element (TAR) and inhibit
HIV-1 transcription by competing with TAR for binding
to p-TEF2b. The impact of PARP1 on HIV-1 infection re-
mains controversial and is likely context-dependent.
In addition to its role in regulating retrovirus replica-
tion, PARylation enhances and represses several other vi-
ruses. This includes herpesviruses, where PARPs have a
wide range of effects. PARP1 and the tankyrase PARP5a
modify the EBV protein EBNA1. PARylation of EBNA1
causes it to dissociate from the dyad symmetry elements,
which restrictsOriP binding and impairs themaintenance
of the viral episome during latency (Deng et al. 2005; Tem-
pera et al. 2010). PARP1 also binds to the TR sequences
in KSHV, which leads to reduced viral genome levels dur-
ing latency. PARP1 and the Ste-20-like kinase hKFC syn-
ergistically bind to andADP-ribosylate/phosphorylate the
γ-2 herpesvirus replication and transcription activator
protein (RTA) (Fig. 4A). These interactions suppress
RTA-mediated transcriptional activation and KSHV lytic
reactivation (Gwack et al. 2003). Two mechanisms have
been described by which γ-herpesviruses counter PARP1
activity. First, it was found that ORF49 of γHV-68 binds
to PARP1, preventing it from interacting with RTA (Fig.
4B). In addition, the processivity factor of KSHV and
γHV-68, PF-8, binds to and targets PARP1 for degradation,
which reduces PARylated RTA and enhances virus repli-
cation (Fig. 4C; Noh et al. 2012; Chung et al. 2015). In con-
trast to the antiviral effects of PARPs during γ-herpesvirus





Figure 4. Mechanisms used by herpesviruses to affect PARyla-
tion and their impact on replication. (A) PARP-1 can bind to
and ADP-ribosylate the γHV RTA, which inhibits its ability to
initiate lytic replication. (B) The γHV-68 protein ORF49 binds
to PARP1 and prevents it from interacting with and ADP-ribosy-
lating RTA, which allows RTA to initiate viral gene transcrip-
tion. (C ) The KSHV and γHV-68 PF-8 proteins bind to PARP1
and target it for ubiquitination and degradation. This again pre-
vents ADP-ribosylation of RTA, which allows it to initiate lytic
replication. (D) The HSV-1 ICP0 protein targets PARG for ubiqui-
tination and degradation, resulting in enhanced PARylation dur-
ing infection and increased replication. (ADPr) ADP-ribose; (Ub)
ubiquitin.
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of HSV-1, the prototype α-herpesvirus. PARP5a (Tankyr-
ase-1) expression was increased and it was translocated
to the nucleus during HSV-1 infection. Knockdown of
both PARP5a and PARP5b resulted in a threefold to four-
fold decrease in virus replication, and inhibition of their
catalytic activity with XAV-939 resulted in a greater
than 1-log reduction in virus replication (Li et al. 2012).
To further indicate that PARP activity is important for vi-
rus replication, HSV-1 infection significantly increased
PARylation. The ICP0 protein targets nuclear forms of
PAR glycohydrolase (PARG), the enzyme that degrades
PAR, for ubiquitination and degradation, providing a pos-
sible mechanism for the dramatic increase in PARylation
during infection (Fig. 4D; Grady et al. 2012).
Finally, poly-ADP-ribosylation is implicated as having
proviral activities in several viral systems. PARP inhibi-
tors have led to greatly reduced infectivity of adenovirus-
es, possibly through the ADP-ribosylation of their core
proteins (Déry et al. 1986). PARP inhibitors also inhibit
JC virus replication (Nukuzuma et al. 2013). PARP1 binds
to the porcine reproductive and respiratory syndrome vi-
rus (PRRSV) nucleocapsid protein, and again, PARP inhib-
itors restricted the replication of PRRSV in cell culture
(Liu et al. 2015b). The nucleocapsid protein of the related
coronaviruses is also ADP-ribosylated, however the im-
pact of this modification on virus replication or pathogen-
esis remains unknown (Grunewald et al. 2018). Last,
PARP activity is required for efficient activity of the
RNA polymerases derived from multiple strains of influ-
enza virus, indicating a potential proviral role for ADP-
ribosylation during influenza infection (Bortz et al.
2011). In summary, PARylation has a variety of different
functions that can both repress and enhance virus
replication.
The roles of nonenzymatic and mono-ADP-
ribosylating PARPs in virus replication
and the antiviral response.
Nonenzymatic and mono-ADP-ribosylating PARPs have
a variety of roles in promoting or inhibiting virus replica-
tion. This class of PARPs include the zinc finger (ZnF)
PARPs (7, 12, and 13), the macrodomain-containing
PARPs (9, 14, and 15), and several PARPs that do not fit
into a specific category (4, 6, 8, 10, and 11). Here, we dis-
cuss what is known about each of these PARPs in the in-
nate immune response to viruses.
CCCH ZnF PARPs
ZnF PARPs contain one or more ZnF domains. These do-
mains are small proteinmotifs that enable these PARPs to
bind RNA. All three ZnF PARPs use this domain to inter-
act with viral RNA and inhibit either translation or
degrade viral RNA, though the specific RNA sequence
that each PARP binds to is likely unique. In addition, all
three ZnF PARPs use either the enzymatic or nonenzy-
matic functions in their PARP domain to impact the in-
nate immune response or virus replication.
PARP13 (ZnF antiviral protein) PARP13, or ZnF antivi-
ral protein (ZAP), was one of the first PARPs identified to
have antiviral activities when, in a screen for antiviral
ISGs, it was found to potently inhibitmurine leukemia vi-
rus (MLV) replication (Gao et al. 2002). Somewhat surpris-
ingly, ZAP lacks the triad motif (H-Y-E) needed for
catalytic activity and has no auto-ADP-ribosylating
activity (Kleine et al. 2008). As such, most of its antiviral
activity is independent of ADP-ribosylation. Since its dis-
covery, ZAP has been shown to inhibit the replication of
several viral families, including retroviruses, alphaviruses,
filoviruses, picornaviruses, herpesviruses, arteriviruses,
orthomyxoviruses, flaviviruses, and hepatitis B virus
(Bick et al. 2003; Muller et al. 2007; Zhu et al. 2011;
Wang et al. 2012; Xuan et al. 2012; Mao et al. 2013; Xuan
et al. 2013; Li et al. 2015, 2015a; Chiu et al. 2018; Xie
et al. 2018; Zhao et al. 2019). ZAP is transcribed into four
different isoforms, with ZAPL and ZAPS being the most
studied (Li et al. 2019). ZAPL contains the inactive PARP
or catalytic domain, while ZAPS does not. ZAPL tends
to have greater antiviral activity, and this may be due, at
least in part, to prenylation of the PARP domain (Charron
et al. 2013; Schwerk et al. 2019). In addition to the PARP
domain, ZAP contains four ZnF-binding domains and a
single WWE domain. ZAP uses its ZnF-binding domains
to bind to viral RNA and recruits both the poly(A)-specific
ribonuclease (PARN) and theRNAexosome to degrade the
viral RNA (Guo et al. 2007). It also inhibits translation by
blocking the interaction between eIF4G and eIF4A, and its
ability to block translation is required for it to degrade
RNA. In addition, ZAP antiviral activity is enhanced by
the ubiquitin ligase activity of TRIM25. TRIM25 binds
to ZAP and ubiquitinates unknown proteins to enhance
the antiviral activity of ZAP (Li et al. 2017; Zheng et al.
2017).
ZAP targets HIV RNAs for degradation, and prefers to
target CG dinucleotides (Takata et al. 2017). Consistent
with this, an HIV-1 mutant with an increased CG content
replicated very poorly in MT4 cells, but that replication
was restored in ZAP-deficient cells. In addition, ZAP tar-
gets the 3′ UTRof Japanese encephalitis virus (JEV), which
contains a high CG content (Chiu et al. 2018). Interesting-
ly, it appears many viruses maintain a low CG dinucleo-
tide level, and the level of ZAP sensitivity of several
viruses mildly correlates with their CG dinucleotide con-
tent (Takata et al. 2017). However, ZAP sensitivity of a
panel of alphaviruses does not correlatewith the CGdinu-
cleotide content found in their genome or individual viral
genes, suggesting that the CG dinucleotide motif is not
the only determinant for ZAP recognition (Li et al.
2019). The localization of ZAP to stress granules also ap-
pears to be functionally important for its antiviral activity
against alphaviruses, as ZAP mutants that do not localize
to SGs are unable to block SINV replication (Law et al.
2019). In vivo, Zap knockout (Zc3hav1−/−) mice showed
enhanced replication of SINV in 10-d-oldmice as expected
(Kozaki et al. 2015). Though surprisingly, in 23-d-old
weanling pups it was shown that a neurovirulent strain
of SINV can use ZAP to decrease its replication in initially
infected cells in vivo such that it prevents immune
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recognition, allowing the virus to spread to the central
nervous system (CNS) and promote disease (Wang et al.
2016).
In addition, different studies have found conflicting re-
sults regarding the ability of ZAP to impact the innate im-
mune response. It was originally found that ZAPS, but not
ZAPL, potentiates RIG-I-dependent type I interferon (IFN-
I) production in human cells by binding to RIG-I via its
ZnF domains and promoting its oligomerization (Fig.
1A; Hayakawa et al. 2011; Chiu et al. 2018). However,
ZAP does not appear to enhance RIG-I-dependent IFN-I
production in mouse cells (Lee et al. 2013). More recent
data indicate that ZAPS may also reduce IFN mRNA by
binding to the 3′ UTR of IFN mRNA and targeting it for
degradation (Fig. 1A; Schwerk et al. 2019). It is conceivable
that ZAP-S uses both functions but in a context-depen-
dent manner.
While ZAPL does not contain an active PARP domain,
in some cases it is required for the ADP-ribosylation of
proteins. For instance, the C terminus of ZAPL binds to
the influenza virus polymerase proteins PB2 and PA,
which causes their subsequent poly-ADP-ribosylation,
ubiquitination, and degradation (Liu et al. 2015a). It is un-
known which PARP and E3 ubiquitin ligase mediates
these effects. Knockdown of ZAPLmodestly increased in-
fluenza virus replication in cell culture, though it is not
clear whether this is due to its ability to bind and target
PB2 and PA for degradation. Interestingly, this ZAPL ac-
tivity was countered by the PB1 protein, which bound to
ZAPL preventing the ubiquitination of PB2 and PA, dem-
onstrating that the virus has evolved ways to neutralize
the antiviral activity of ZAP (Fig. 5A). In addition to
PB1, several other viral proteins have been found to coun-
ter ZAP using multiple mechanisms (Fig. 5B–D). Influen-
za A NS1 prevents ZAP-S from binding to its target RNA
(Tang et al. 2017), γHV-68 RTA disrupts the intermolecu-
lar interaction of ZAP (Xuan et al. 2013), HSV-1 UL41 de-
grades ZAP mRNA (Su et al. 2015), and, finally, the
enterovirus (EV)-71 3C protease cleaves ZAP protein
(Xie et al. 2018). Due to its broad-spectrum antiviral activ-
ity, it is likely there are evenmore viral proteins that func-
tion to counter ZAP.
PARP12 PARP12 is a mono-ADP-ribosyltransferase and
has four or five N-terminal CCCH-type zinc finger (ZnF)
domains that are important for RNA binding, one or two
WWEdomains in themiddle of the protein that are impor-
tant for ADP-ribose binding, and a PARP domain at the C
terminus, which provides the protein with mono-ADP-
ribosylating activity (Welsby et al. 2014). There are two
splice forms of PARP12 mRNA, PARP12L, and PARP12S
(Atasheva et al. 2012). PARP12L contains both the ZnF
domains and the PARP catalytic domain, while PARP12S
has the ZnF domains but lacks the PARP catalytic
domain.
As described above, PARP12 translocates to cytoplas-
mic stress granules upon cell stress (Leung et al. 2011;
Welsby et al. 2014). PARP12 initially localizes to the
trans-Golgi network (TGN) and translocates to stress
granules during stress stimuli in several different cell
types. This activity has been linked to the ZnF domains,
as mutations in the ZnF domains abrogated the ability
of PARP12 to move to stress granules (Welsby et al.
2014). The translocation of PARP12 may also depend on
PARP1 acting as a stress sensor in the nucleus, as an in-
crease in unconjugated PAR is a key factor that promotes
the recruitment of PARP12 to stress granules (Catara et al.
2017). The translocation of PARP12 to stress granules is
reversible, as it relocates back to the Golgi once the stress
is relieved.
The antiviral role of PARP12 was first described in an
overexpression screen, where it mildly inhibited the repli-
cation of both VSV andMHV-68 (Liu et al. 2012b). Shortly
after this, another study found that PARP12 was differen-
tially expressed in cells that cleared VEEV replication
compared with those that were persistently infected (Ata-
sheva et al. 2012). Further analysis showed that PARP12L,
but not PARP12S, expression from a VEEV replicon or
virus restricts VEEV replication, as well as several other
viruses including Sindbis virus (SINV), encephalomyocar-
ditis virus (EMCV), vesicular stomatitis virus (VSV), Rift
Valley fever virus (RVFV), and chikungunya virus
(CHIKV). Subsequently, this group showed that PARP12
strongly inhibited both cellular and viral translation (Ata-
sheva et al. 2014). Immunoprecipitation with PARP12
identified several ribosomal proteins and translation and
elongation factors, indicating that PARP12 interacts
with ribosomes. Interestingly, PARP12 required its enzy-





Figure 5. Viral mechanisms of ZAP antagonism. (A) IAV protein
PB1 binds to ZAP, which prevents its interaction with the PA and
PB2 proteins that otherwise would lead to PARylation, ubiquiti-
nation, and degradation of these proteins. (B) IAV NS1 and γHV-
68 RTA proteins interact with ZAP, preventing its association
with viral RNA. (C ) The EV-71 3C protease cleaves ZAP to pre-
vent it from accumulating. (D) HSV-1 UL41 protein cleaves
ZAP mRNA to prevent its translation. (ADPr) ADP-ribose; (Ub)
ubiquitin.
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replication, indicating that PARP12 may use distinct
mechanisms to block virus replication and cellular
translation.
Additionally, PARP12 was identified in a screen for
ISGs that inhibit Zika virus (ZIKV) (Li et al. 2018). Using
both knockout cells and overexpression, the authors
showed that PARP12 was both necessary and sufficient
for the inhibition of ZIKV replication. PARP12 was re-
quired for the ADP-ribosylation, ubiquitination, and
subsequent degradation of ZIKV NS1 and NS3 proteins.
This activity did not require either the ZnF or WWE do-
mains of PARP, but did require its catalytic domain, as
an inactive catalytic domain reversed the regulatory ef-
fects of PARP12 on viral protein degradation. Interesting-
ly, NS1 and NS3 appeared to be poly-ADP-ribosylated,
indicating that PARP12 may work with another PARP
to mediate the poly-ADP-ribosylation of these proteins.
PARP12 also has a role in the restriction of coronavirus
(CoV) replication, as siRNA knockdown of PARP12
partially restored replication of MHV lacking the ADP-
ribosylhydrolase (ARH) activity of the CoV macrodomain
(Grunewald et al. 2019a). The mechanism used by
PARP12 to restrict MHV replication remains unknown.
Finally, PARP12was also shown to enhanceNF-κB signal-
ing, possibly by interacting with TRIF (Fig. 1A; Welsby
et al. 2014).
PARP7 (TiPARP) PARP7, also known as tetrachlorodi-
benzo-p-dioxin (TCDD)-inducible poly-ADP-ribose poly-
merase (TiPARP), has a single ZnF domain that
mediates RNA binding. It also has a WWE domain and a
PARP catalytic domain capable of mono-ADP-ribosyla-
tion (Kozaki et al. 2017).
Like PARP12, TiPARP was also shown to block VEEV
replication and inhibit cellular translation when trans-
duced into cells by a VEEV replicon (Atasheva et al.
2014). In a separate study, siRNA knockdown of TiPARP
inU373 human astrocyte cells led to increased replication
of SINV and rubella virus replication (Kozaki et al. 2017).
The increase in SINV replication was also demonstrated
in TiParp−/− mice. TiPARP-mediated inhibition of SINV
was dependent on its ZnF domain, which binds to SINV
RNAand recruits RNAdegradation factors to sites of viral
replication. This suggests thatTiPARP recognizes specific
virus RNAs for degradation, however the target specificity
of TiPARP is still unknown.
TiPARP also has proviral effects in addition to its anti-
viral functions. TiPARP negatively regulates the type I
IFN response by ADP-ribosylating TBK1 (Fig. 1A; Yamada
et al. 2016). The ADP-ribosylation of the kinase domain of
TBK1 suppresses IFN production. It was suggested that
negative regulation of IFN production by TiPARP may
help protect the cell from the harmful effects of type I
IFN. The same study found that the loss of TiPARP led
to decreased IAV replication, which strongly correlated
with increased IFN-I production. Our group has also found
that siRNA knockdown of TiPARP led to decreased repli-
cation of MHV and increased IFN-I production, further in-
dicating TiPARP as a proviral factor for some viruses
(Grunewald et al. 2019a,b). However, it remains unclear
whether the ability of TiPARP to enhance MHV or IAV
replication is tied to its ability to block the IFN-I response.
Macrodomain-containing PARPs
The macro PARPs contain two (PARP9/PARP15) or three
(PARP14) macrodomains that mediate binding to ADP-ri-
bose, as described above. While some macrodomains can
cleaveADP-ribose from a substrate, it is likely thatmacro-
domains within these PARP proteins only bind ADP-ri-
bose. All three macro PARPs are rapidly evolving
(Daugherty et al. 2014), and PARP15 has been identified
in stress granules (Leung et al. 2011); however, direct evi-
dence of their involvement in virus infections is limited.
No study has identified a role for PARP15 in modulating
virus infection or the innate immune response, and thus
it will not be discussed further.
PARP9 (BAL1) PARP9 was originally termed B-aggres-
sive lymphoma 1 gene (BAL1) as it was identified as a
risk factor for large diffuse B-cell lymphomas (Aguiar
et al. 2005). It is catalytically inactive, at least when ex-
pressed by itself, but can ADP-ribosylate ubiquitin in
the presence of an E3 ubiquitin ligase, DTX3L (Yang
et al. 2017). As described above, PARP9 promotes
STAT1 phosphorylation, proinflammatory gene expres-
sion, and differentiation into M1-like macrophages (Iwata
et al. 2016). In the antiviral response, PARP9 expression in
malignant B-cell lymphoma lines can lead to widespread
induction of ISG expression (Juszczynski et al. 2006).
Zhang et al. (2015) found that the complex of PARP9
and DTX3L attached to STAT1 to mediate the hyper-re-
sponsiveness of a mutant STAT1 protein (STAT1-CC).
The PARP9–DTX3L complex ubiquitinates histone pro-
teins, most notably H2BJ, which led to chromatin remod-
eling and enhanced expression of at least a subset of ISGs
(Fig. 1B). This interaction was necessary and sufficient to
inhibit the replication of multiple viruses, including
EMCV, IAV, and SINV. The PARP9–DTX3L complex
also ubiquitinates the EMCV 3C protease, which led to
its degradation, but this effect was mostly, if not
completely, due to DTX3L activity.
PARP14 (CoaST-6) PARP14 was originally identified as
Collaborator of STAT6 (CoaST6) (Goenka and Boothby
2006). It has a range of effects on cell physiology and im-
munity that were largely anti-inflammatory (Cho et al.
2011, 2013; Barbarulo et al. 2013; Vyas et al. 2013; Ian-
sante et al. 2015; Iwata et al. 2016; Krishnamurthy and
Kaplan 2016). In the antiviral response, PARP14 instead
is required to enhance IFN-I production in RAW cells
(transformed peritoneal macrophages) following LPS
treatment (Caprara et al. 2018), in primary macrophage
cells during CoV infection, and following treatment of hu-
man A549 cells with poly(I:C) (Grunewald et al. 2019a).
Following LPS treatment, PARP14-deficient cells showed
similar levels of IRF-3 phosphorylation and nuclear trans-
location, but had reduced levels of Pol II recruited to the
promoters of IRF-3-dependent genes (Caprara et al.
2018). There was also a dramatic reduction in H3K27
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acetylation, a known marker of active promoters and en-
hancers (Fig. 1A). It is unclear whether this function of
PARP14 is dependent on its catalytic activity. It is also
not yet known whether PARP14 has the same function
in the cellular response to virus infection or poly(I:C).
These two studies also found that PARP14 was required
to restrict the replication of S. typhimurium and an
ARH-deficient MHV, though it is not known whether
the ability of PARP14 to inhibit these pathogens is tied
to its role in up-regulating IFN production or whether
these are distinct functions of PARP14. It is important
to note that these experiments were donewith undifferen-
tiated or M0 macrophages, while other studies where
PARP-14 was found to have anti-inflammatory functions
used M1 or M2 macrophages, differentiated by further
IFN-γ or IL-4 treatment. This suggests that PARP14 func-
tion is likely context-dependent.
Other PARPs
The final class of PARPs do not fit into any of the other de-
fined classes of PARPs, have no similar domains other
than the PARP domain, and are thus simply termed “oth-
er PARPs.” These PARPs include PARPs 4, 6, 8, 10, 11,
and 16. PARP6 and PARP8 have no defined domains be-
sides their PARP domain, and neither have a known role
in the immune response. PARP4, while rapidly evolving
as described earlier, has not been reported to have any di-
rect antiviral or proviral activity. PARP16 promotes ER
stress responses by ADP-ribosylating IRE1α and PERK
(Jwa and Chang 2012), and also ADP-ribosylates Karyo-
pherin β1, indicating a potential role in nuclear transport
(Di Paola et al. 2012). However, it also has no known anti-
viral activities or impact on the innate immune response.
Here we focus on PARP10 and PARP11.
PARP10 PARP10 contains both an RNA recognition
motif (RRM), nuclear import and export signals, and two
ubiquitin-interacting motifs (UIM) in addition to its cata-
lytic domain (Verheugd et al. 2013) and is highly up-regu-
lated by IFN (Eckei et al. 2017; Grunewald et al. 2019a).
Along with PARP12 and PARP7, it inhibits VEEV replica-
tion and blocks protein translation when expressed from a
VEEV replicon (Atasheva et al. 2014). PARP10 also blocks
NF-κB signaling and the production of proinflammatory
cytokines (Verheugd et al. 2013). Mechanistically, the
UIM of PARP10 interacts with K63-linked ubiquitin
chains and NEMO. PARP10 ADP-ribosylates NEMO
and prevents its polyubiquitination, which ultimately
blocksNF-κB from translocating to the nucleus to activate
gene expression (Fig. 1A). It remains unknown whether
this function of PARP10 impacts host–pathogen interac-
tions or whether it functions in other contexts.
PARP11 PARP11 is the second smallest PARP protein
(PARP16 is the smallest), with only a singleWWE domain
in addition to its ART domain, and is also highly up-regu-
lated by IFN (Grunewald et al. 2019a). Recently, PARP11
was shown to block IFN signaling by ADP-ribosylating
the E3 ubiquitin ligase β-transducin repeat-containing
protein (β-TrCP), which lead to the ubiquitination and
degradation of the interferon α/β receptor (IFNAR) (Fig.
1B; Guo et al. 2019). siRNA silencing of PARP11 or treat-
ment with rucaparib, a pan-PARP inhibitor used in ad-
vanced ovarian cancer, inhibited the replication of VSV
and HSV-1. While normally known to inhibit PARP1/2,
at the concentrations of drug used in this study rucaparib
appeared to preferentially target PARP11. Interestingly,
following infection in vivo, rucaparib enhanced IFN-I sig-
naling, reduced VSV replication in multiple organs, and
led to better outcomes for the mice infected with either
VSV or HSV-1. These data indicate that PARP11-specific
inhibitors could be a usefulmeans of treating specific viral
infections.
In summary, several of the nonenzymatic or mono-
ADP-ribosylating PARPs are potent antiviral proteins
that are able to inhibit viruses from several different viral
families. However, some do contain activities that pro-
mote virus replication. While some mechanisms are
known, including blocking translation, degrading RNA,
and targeting viral or host proteins for ubiquitination
and degradation, many mechanisms are still unknown.
However, recent reports are making it clear that in
many, but not all cases, ADP-ribosylation is tied to pro-
tein homeostasis, either through mediating translation
or ubiquitination-dependent protein degradation. In addi-
tion, several studies have identifiedmultiple points where
the innate immune response is modulated by PARPs and
ADP-ribosylation (Fig. 1). The identification of similar and
potentially novel processes mediated by PARPs in virus
infections will likely be uncovered in the near future.
Final remarks
With the advent of new mass spectrometry techniques
and improved tools for detecting ADP-ribose, the last dec-
ade has seen an explosion in our understanding of how
PARPs and ADP-ribose impact not just immunity, but
biology in general. This technological development is ex-
ponential, which will further facilitate PARP research in
the future. PARP inhibitors are being tested in the clinic
for chemotherapy, so it is likely that PARP inhibitors or
agonists could be useful for treating immune disorders
as well. However, developing PARP-specific inhibitors
or agonists will be challenging. There is still a long way
to go before we fully understand how PARPs function
both in cell culture and in vivo to target them for the treat-
ment of infections or immune diseases. Additional PARP-
deficient animals and specific inhibitors are needed to
gain a better knowledge of how PARPs impact pathogen-
esis from infection or immune-mediated diseases. While
PARPs are structurally and functionally distinct, specific-
ity and off-target effects of PARP inhibitors remain in-
completely understood; thus, further characterization of
each compound is necessary.
Accumulating clinical and scientific evidence supports
a theory that inflammation promotes various global
health threats such as myocardial infarction. However,
mechanisms of macrophage activation, for instance,
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remain obscure. Recent understanding that macrophages
are highly heterogeneous has added to the complexity of
inflammation.What is the role of each PARP in inflamma-
tion via an enzymatic activity-dependent or independent
mechanism? What is a specific function of each domain
in macrophage activation? Furthermore, additional roles
for PARPs in the antiviral response are likely to exist, es-
pecially for PARPs that are under strong positive selection
pressure, but have yet to be associated with a specific bio-
logical activity. In several cases the mechanism used by
PARPs to inhibit specific viruses remain unknown. It is
also intriguing that several IFN-induced PARPs have
been shown to enhance virus replication. Could this be
a mechanism by the host to maintain a minimal amount
of virus replication in vivo so that the immune system can
be appropriately activated? The answers to these and
many other questions will be of great interest to PARP re-
searchers, immunologists, andmicrobiologists as they are
likely to uncover unique cellular processes regulated by
ADP-ribosylation that could lead to the identification of
novel therapeutic targets for infections or immune-medi-
ated diseases.
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